Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxosmithkline Intellectual Property Limited

Matthew Campbell

Christopher Roland Wellaway

Michael David Barker

Neil Stuart Garton

Ann Louise Walker

John Liddle

David Matthew Wilson

Stephen John Atkinson

Robert John Sheppard

Clement Douault

Hawa Diallo

Dominique Amans

Paul Bamborough

Matthew John Lindon

Susan Marie Westaway

John Alexander Brown

Rino Antonio Bit

Natalie Hope Theodoulou

Tracy Jane Shipley

Jessica Fanny Renaux

William Henry Miller

Alan D Borthwick

Julie Nicole Hamblin

Andrew McMurtrie Mason

Nigel Stephen Watson

Chuen Chan

Robert John Young

Henry Anderson Kelly

Nigel Paul King

Stefan Senger

Kenneth David Down

Savvas Kleanthous

Paul William Smith

Sophie Marie Bertrand

Andrew Baxter

Curt Dale Haffner

Zoe Alicia Henley

Eric Philippe Andre Talbot

Jonathan Andrew Taylor

Matthew J Lindon

Christopher Wellaway

The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity. 

Oxepinopyrazole derivatives as inhibitors of P13-kinase activity

Compounds of formula (I): wherein X, Y, Rand R-Rare as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

Benzoimidazole derivatives as PAD4 inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.

2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors

The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.

Furopyridines as bromodomain inhibitors

Thienopyridone compounds of formula (I): or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors

Compounds of formula (I) wherein; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl-O&#x2014;, or Calkoxy; Ris hydrogen, Calkyl, or CalkoxyCalkyl; Ris hydrogen, Calkyl, perhalomethylCalkyl; or unsubstituted CcycloalkylCalkyl; A is C&#x2014;Ror N; B is C&#x2014;Ror N; D is C&#x2014;Ror N; with the proviso that at least one of A, B, and D, is N; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, Calkoxy, or hydroxy; Ris hydrogen or Calkyl, with the proviso that one of Rand Ris hydrogen; Ris hydrogen or hydroxy; Ris hydrogen or Calkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis. 

2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors

2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors

The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same. 

2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors

Growing community of inventors

Stevenage, United Kingdom

Matthew Campbell